PDCD1 and neoplasm: More recently, the use of the anti-PD-1, pembrolizumab, has been approved for the treatment of all solid tumors with tumor mutational burden (TMB) equal to or greater than 10 mutations/megabase as measured by the FoundationOne CDx assay.